Owning 39% shares,hedge funds owners seem interested in Immunic, Inc. (NASDAQ:IMUX), [Yahoo! Finance]
Immunic, Inc. (IMUX)
Company Research
Source: Yahoo! Finance
51% of the business is held by the top 7 shareholders Using data from analyst forecasts alongside ownership research, one can better assess the future performance of a company A look at the shareholders of Immunic, Inc. ( NASDAQ:IMUX ) can tell us which group is most powerful. The group holding the most number of shares in the company, around 39% to be precise, is hedge funds. In other words, the group stands to gain the most (or lose the most) from their investment into the company. Because hedge funds owners have a huge pool of resources and liquidity, their investing decisions tend to carry a great deal of weight, especially with individual investors. As a result, a sizeable amount of institutional money invested in a firm is generally viewed as a positive attribute. Let's delve deeper into each type of owner of Immunic, beginning with the chart below. What Does The Institutional Ownership Tell Us About Immunic? Institutional investors commonly compare their own return
Show less
Read more
Impact Snapshot
Event Time:
IMUX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IMUX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IMUX alerts
High impacting Immunic, Inc. news events
Weekly update
A roundup of the hottest topics
IMUX
News
- Insider Buys Additional US$100k In Immunic Stock [Yahoo! Finance]Yahoo! Finance
- 75+ Key Companies Charting New Frontiers in Multiple Sclerosis Therapeutic Space | DelveInsight [Yahoo! Finance]Yahoo! Finance
- Immunic Announces Publication of Data From Phase 1/1b Clinical Trial of IMU-856 in the Peer Reviewed Journal, The Lancet Gastroenterology & HepatologyPR Newswire
- Immunic, Inc. (NASDAQ: IMUX) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.MarketBeat
- Immunic to Present at the November 21st Virtual Investor Summit Microcap EventAccesswire
IMUX
Earnings
- 11/7/24 - Miss
IMUX
Sec Filings
- 11/14/24 - Form SC
- 11/14/24 - Form SC
- 11/14/24 - Form SC
- IMUX's page on the SEC website